[EN] RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS [FR] ACIDES RIBONUCLÉIQUES AYANT DES NUCLÉOTIDES 4'-THIO-MODIFIÉS ET PROCÉDÉS ASSOCIÉS
[EN] RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS [FR] ACIDES RIBONUCLÉIQUES AYANT DES NUCLÉOTIDES 4'-THIO-MODIFIÉS ET PROCÉDÉS ASSOCIÉS
RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
申请人:SHIRE HUMAN GENETIC THERAPIES, INC.
公开号:US20160031928A1
公开(公告)日:2016-02-04
Disclosed are messenger RNA molecules and related compositions incorporating a 4′-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4′-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.
Ribonucleic acids with 4′-thio-modified nucleotides and related methods
申请人:TRANSLATE BIO, INC.
公开号:US10266559B2
公开(公告)日:2019-04-23
Disclosed are messenger RNA molecules and related compositions incorporating a 4′-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4′-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.
RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
申请人:Translate Bio, Inc.
公开号:EP2970351B1
公开(公告)日:2017-09-13
[EN] RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS<br/>[FR] ACIDES RIBONUCLÉIQUES AYANT DES NUCLÉOTIDES 4'-THIO-MODIFIÉS ET PROCÉDÉS ASSOCIÉS
申请人:SHIRE HUMAN GENETIC THERAPIES
公开号:WO2014152513A1
公开(公告)日:2014-09-25
Disclosed are messenger RNA molecules and related compositions incorporating a 4'-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein invivo and to treat or prevent diseases or disorders. In certain embodiments, the 4'-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.